2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer (NSCLC).
Molecular testing is routinely ordered for patients with de novo metastatic NSCLC or recurrent disease following prior curative-intent therapy, Langer explains. Although testing isn’t ordered for all patients, it should be done in patients with nonsquamous NSCLC regardless of smoking history and nonsmokers or remote former smokers regardless of histology.
Additionally, it is possible routine molecular testing will be done for all patients with NSCLC in the next 1 to 2 years because an increasing number of molecular abnormalities, including EGFR mutations and MET amplifications, have been identified in patients with squamous histology, Langer concludes.
Related Content: